Latest close
$87.55
As of Oct 13, 2026
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Fairfax Financial Holdings | 10.63% | 2,712,000 | HELD |
| Davis Advisors | 5.27% | 11,865,916 | TRIMMED (-3.1%) |
| Patient Capital Management | 4.19% | 1,235,505 | TRIMMED (-9.0%) |
| Hillman Capital Management | 4.15% | 55,475 | TRIMMED (-17.8%) |
| Pzena Investment Management | 3.57% | 11,769,536 | TRIMMED (-14.5%) |
| Dodge & Cox Funds | 2.71% | 50,012,765 | TRIMMED (-3.4%) |
| Viking Global Investors | 1.08% | 3,663,361 | NEW |
| Ariel Investments | 0.75% | 730,110 | ADDED (+4.0%) |
| Oakmark Funds | 0.05% | 335,817 | TRIMMED (-32.0%) |
| Matrix Asset Advisors | 0.05% | 6,175 | HELD |
Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end. Fund counts here aggregate every share class mapped to this ticker; research headlines cite filer counts as they stood at publication, so a count here can differ from a headline by a holder (see Methodology, "How holder counts are counted").
Exited this quarter: Maverick Capital, Tweedy Browne.
| Institutions holding | 2,075 of 8,857 filers |
| Long-only filers among them | 2,062 |
| Change vs 2026 Q1 | +225 net · 1,631 entered · 1,406 exited |
| Shares reported, all filers | 1,130,618,041 |
| Reported value, all filers | $115.0B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Retail-Drug Stores and Proprietary Stores (SIC 5912) |
| Revenue · FY2025 | $402.1B |
| Net income · FY2025 | $1.8B |
| Total assets · FY2025 | $253.5B |
| Shares outstanding | 1,278,970,369 |
| Market cap (at latest close) | $112.0B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 7, 2026. Shares outstanding as reported Jul 29, 2026.
| Shares short · Sep 15, 2026 | 16,123,980 |
| Share of shares outstanding | 1.26% |
| Days to cover | 3.14 |
Shares short at recent settlements — Jun 30, 2026: 19.9M · Jul 15, 2026: 19.5M · Jul 31, 2026: 18.7M · Aug 14, 2026: 16.8M · Aug 31, 2026: 18.1M · Sep 15, 2026: 16.1M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 29, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the 90 days to Oct 14, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Oct 3, 2026).
Financial Screens
· Growth — Revenue up every year for 5 straight years
· Dividend Growth — Dividends raised for more than 10 years
· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Shareholder Yield — Cash returned through dividends and buybacks
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
Key figures
· Growth — Latest revenue: $402.1B · 5-yr revenue CAGR: 8.4% · Straight growth years: 15
· Dividend Growth — Dividend per share: 2.66 · Dividend yield: 3.0% · Straight dividend years: 19 · 10-yr dividend growth: 56.5%
· Cash Flow (FCF) — Latest FCF: $7.8B · FCF yield: 7.0% · Positive FCF years: 3
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 3.20 · Operating cash flow: $10.6B · Net income: $1.8B
· Shareholder Yield — Shareholder yield: 3.0% · of which dividends: 3.0% · of which buybacks: 0.0%
· Distress Risk (Altman Z″) — Z″-Score: 0.99 · Working capital / assets: -0.06 · Retained earnings / assets: 0.24 · EBIT / assets: 0.02 · Equity / liabilities: 0.42
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Super-investor 13F BEST — appeared in 12 of the last 20 quarterly lists; latest 2026 Q2, ranked #49 of 50.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2024 Q2, ranked #44 of 50.
· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2021 Q4, ranked #16 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 14 | 57.1% | +3.3% | +2.8% | +0.5% |
| Share count tripled (3x) | 3 | 66.7% | +3.1% | +4.8% | -1.7% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold CVS: Alphabet Inc. (GOOGL) · MICROSOFT CORP (MSFT) · TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (TSM) · CAPITAL ONE FINANCIAL CORP (COF) · JPMORGAN CHASE & CO (JPM) · FISERV INC (FISV) · AMAZON COM INC (AMZN) · Meta Platforms, Inc. (META) · NVIDIA CORP (NVDA) · BANK OF AMERICA CORP /DE/ (BAC).
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.